Mucocutaneous Lymph Node Syndrome: Clinical Trials

13 trials for Mucocutaneous Lymph Node Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 13 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 313Completed 8, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 21Not yet recruiting 1

Follow Mucocutaneous Lymph Node Syndrome: new trials by email Literature Review of Mucocutaneous Lymph Node Syndrome trials Research Report on Mucocutaneous Lymph Node Syndrome

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
IVIG, Aspirin, Firsekibart - Kawasaki Disease
Phase 2 / Phase 3Not yet recruitingChildren's Hospital of Fudan University902026-11-012026-10-22
Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities
atorvastatin of dose level 1, atorvastatin of dose level 2, atorvastatin of dose level 3 - Kawasaki Disease, Coronary Artery Abnormalities
Phase 3RecruitingChildren's Hospital of Fudan University92026-06-082026-06-16
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
ANAKINRA, Intravenous immunoglobulin - Kawasaki Disease
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris842023-10-202024-02-28
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
IVIG, Aspirin, Infliximab - Kawasaki Disease
Phase 3WithdrawnChildren's Hospital of Fudan University2020-10-012021-03-12
Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease
IVIG, Aspirin, Prednisolone - Kawasaki Disease
Phase 3CompletedChildren's Hospital of Fudan University32082020-01-152026-04-16
KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
IVIG, Infliximab - Mucocutaneous Lymph Node Syndrome
Phase 3CompletedUniversity of California, San Diego1052017-02-172021-12-03
Different Doses of IVIG for Kawasaki Disease
IVIG (1g/kg,once), IVIG (1g/kg,twice), IVIG (2g/kg.once) - Kawasaki Disease
Phase 3CompletedChildren's Hospital of Fudan University4042014-01-012018-05-11
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
Prednisolone, immunoglobulin - Kawasaki Disease, Steroid
Phase 3UnknownNational Taiwan University Hospital1002013-10-172017-06-27
Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial
Infliximab, IVIG - Kawasaki Disease
Phase 3CompletedFudan University402013-01-012016-02-03
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH) - Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Phase 3CompletedTanabe Pharma Corporation312012-05-012026-01-07
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
Infliximab, Placebo - Kawasaki Disease
Phase 3CompletedUniversity of California, San Diego1962009-03-012014-11-24
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
Sestamibi - Kawasaki Disease
Phase 3CompletedLantheus Medical Imaging4452005-08-012019-07-23
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
Immune Globulin Intravenous (Human), 10% - Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP)
Phase 3CompletedBaxalta now part of Shire612002-06-252021-08-24

Narrower conditions

Immunologic Deficiency Syndromes (1)  ·  Primary Immunodeficiency Diseases (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)

Broader conditions

Cardiovascular Diseases (13)  ·  Hemic and Lymphatic Diseases (13)  ·  Lymphatic Diseases (13)  ·  Skin Diseases (13)  ·  Skin Diseases, Vascular (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Vascular Diseases (13)  ·  Vasculitis (13)  ·  Autoimmune Diseases (1)  ·  Blood Coagulation Disorders (1)  ·  Blood Platelet Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Cytopenia (1)  ·  Genetic Diseases, Inborn (1)  ·  Hematologic Diseases (1)

Interventions

Immunoglobulins, Intravenous (7)  ·  Infliximab (4)  ·  Aspirin (3)  ·  Prednisolone (2)  ·  Immunoglobulins (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Interleukins (1)  ·  Technetium Tc 99m Sestamibi (1)  ·  acetylsalicylic acid lysinate (1)  ·  gamma-Globulins (1)

Sponsors

Children's Hospital of Fudan University (5)  ·  University of California, San Diego (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Baxalta now part of Shire (1)  ·  Fudan University (1)  ·  Lantheus Medical Imaging (1)  ·  National Taiwan University Hospital (1)  ·  Tanabe Pharma Corporation (1)

Countries

China (6)  ·  United States (4)  ·  Taiwan (2)  ·  Brazil (1)  ·  Canada (1)  ·  France (1)  ·  Japan (1)  ·  Philippines (1)  ·  South Korea (1)  ·  Thailand (1)

Top investigators

Adriana H. Tremoulet, M.D. (1)  ·  Chen Chu, MD (1)  ·  Fang Liu, MD (1)  ·  Fang Liu, MD. (1)  ·  Guoying Huang, MD. (1)  ·  Guoying Huang, PHD (1)  ·  Jane C Burns, M.D. (1)  ·  Jane C Burns, MD (1)  ·  Masaaki Mori, MD (1)  ·  Mei-Hwan Wu, MD, PhD (1)  ·  Ming-Tai Lin, MD, PhD (1)  ·  Octavio Ramilo, M.D. (1)  ·  Qi Zhu, MD, (1)

Results publications

PMID 23305955, PMID 23901839, PMID 24572997, PMID 29386515, PMID 33600060, PMID 34715057, PMID 34895290, PMID 41985133